FDA declines to grant accelerated approval for Eli Lilly's experimental Alzheimer's treatment | CNN

The US Food and Drug Administration declined to grant accelerated approval to an experimental Alzheimer’s drug, donanemab, and requested additional data from Eli Lilly and Company, the drug maker. The company, which announced the development on Thursday, plans to file Phase 3 clinical trial data later this year for a traditional FDA approval.

The Alzheimer’s Drug Discovery Foundation released a statement Thursday in response to the FDA decision, describing it as being due to “the limited number of patients” who stayed on donanemab for at least 12 months, which is the timeframe the FDA wants to see to assess the drug’s safety.

I hope Nuremberg2 comes soon enough for the graphene shot depopulation agenda pushers.

Joe is a Joke!

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA rejects Eli Lilly's proposed Alzheimer's treatment, says more data neededThe setback could delay a potential commercial introduction of the highly anticipated drug by at least several months, if the Food and Drug Administration... Don't get us started on big pharma concerns when it involves such a needed treatment respecting Alzheimer's people and their families. Safety and clinical trials no doubt are involved as the Covid business gushed with profits for stakeholder/shareholders? Yes, of course. Academic But it green-lighted the untested Covid vaccines...
Source: MarketWatch - 🏆 3. / 97 Read more »

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analystsThe U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by months, analysts said.
Source: Reuters - 🏆 2. / 97 Read more »